Pelthos Therapeutics Inc (PTHS) Q1 2026 Earnings Call Transcript

Why It Matters

The surge in recurring BRIUMVI sales and expanded guidance underscore a durable growth engine in the competitive multiple‑sclerosis market, while pipeline advances could double the franchise’s addressable market.

Key Takeaways

• U.S. BRIUMVI revenue $195M, beating guidance.
• Year‑over‑year growth 63% in U.S. sales.
• Full‑year U.S. guidance lifted to $885‑$900M.
• Over 25,000 patients prescribed globally.
• Subcutaneous BRIUMVI Phase III fully enrolled, data year‑end.

Pulse Analysis

Pelthos Therapeutics is capitalizing on a maturing multiple‑sclerosis landscape, where its CD20‑targeted antibody BRIUMVI has become a leading IV therapy. The Q1 2026 results showcase a $195 million U.S. net product revenue, outpacing guidance and delivering a 63% YoY increase. This momentum reflects strong physician adoption, high treatment persistence, and a recurring revenue model that builds a growing patient base rather than resetting each year. By securing the #1 dynamic share in private‑practice infusion settings, Pelthos is establishing a defensible market position against entrenched competitors.

Beyond the IV franchise, Pelthos is poised to unlock a new growth frontier through its subcutaneous BRIUMVI program. The Phase III trial, now fully enrolled, targets the roughly 35% of the anti‑CD20 market that prefers self‑administration, potentially expanding the addressable market by nearly double. Simultaneously, the ENHANCE study aims to simplify initiation with a single‑dose regimen, which could enhance operational efficiency and patient convenience. These pipeline milestones, coupled with exploratory indications in Myasthenia Gravis and treatment‑resistant schizophrenia, signal a strategic diversification that could sustain long‑term revenue expansion.

Financially, Pelthos entered the quarter with $573 million in cash and equivalents, bolstered by a recent financing arrangement with Blue Owl. The company allocated $100 million to share repurchases, reflecting confidence in its undervalued stock while preserving flexibility for strategic investments. With operating income rising to $34.8 million and net income to $19.8 million, the firm demonstrates disciplined expense growth relative to revenue. The raised guidance and near‑$1 billion run rate set a clear trajectory for investors, positioning Pelthos as a compelling play in the high‑growth, high‑margin biotech sector.